Literature DB >> 3484655

Irritable bowel syndrome: prevalence, prognosis and consequences.

W G Thompson.   

Abstract

Entities:  

Mesh：

Year:  1986        PMID： 3484655      PMCID： PMC1490645     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  29 in total

1.  Recurrent abdominal pains: a field survey of 1,000 school children.

Authors:  J APLEY; N NAISH
Journal:  Arch Dis Child       Date:  1958-04       Impact factor: 3.791

2.  Long-term prognosis in children with recurrent abdominal pain.

Authors:  M F Christensen; O Mortensen
Journal:  Arch Dis Child       Date:  1975-02       Impact factor: 3.791

3.  Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease.

Authors:  D P Burkitt; A R Walker; N S Painter
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

4.  Prognosis in the irritable-bowel syndrome. A prospective study.

Authors:  S L Waller; J J Misiewicz
Journal:  Lancet       Date:  1969-10-11       Impact factor: 79.321

5.  Functional disorders of the colon.

Authors:  A K Bordie
Journal:  J Indian Med Assoc       Date:  1972-06-16

6.  Clinical diagnosis of the irritable colon syndrome.

Authors:  K Goulston
Journal:  Med J Aust       Date:  1972-05-27       Impact factor: 7.738

7.  Frequency of "functional" gastrointestinal disorders.

Authors:  A Ferguson; W Sircus; M A Eastwood
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

8.  A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease.

Authors:  W Kruis; C Thieme; M Weinzierl; P Schüssler; J Holl; W Paulus
Journal:  Gastroenterology       Date:  1984-07       Impact factor: 22.682

9.  Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer.

Authors:  W E Whitehead; C Winget; A S Fedoravicius; S Wooley; B Blackwell
Journal:  Dig Dis Sci       Date:  1982-03       Impact factor: 3.199

10.  Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease.

Authors:  W G Thompson
Journal:  Gut       Date:  1984-10       Impact factor: 23.059
View more
  12 in total

1.  Alternatives to medicine.

Authors:  W G Thompson
Journal:  CMAJ       Date:  1990-01-15       Impact factor: 8.262

Review 2.  The irritable bowel syndrome.

Authors:  C Y Francis; P J Whorwell
Journal:  Postgrad Med J       Date:  1997-01       Impact factor: 2.401

Review 3.  The extracolonic manifestations of the irritable bowel syndrome.

Authors:  K Tilbe; S Sullivan
Journal:  CMAJ       Date:  1990-03-15       Impact factor: 8.262

Review 4.  Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms?

Authors:  S E Kim; L Chang
Journal:  Neurogastroenterol Motil       Date:  2012-08-02       Impact factor: 3.598

Review 5.  Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants.

Authors:  W G Paterson; W G Thompson; S J Vanner; T R Faloon; W W Rosser; R W Birtwhistle; J L Morse; T A Touzel
Journal:  CMAJ       Date:  1999-07-27       Impact factor: 8.262

Review 6.  Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review.

Authors:  F A Luscombe
Journal:  Qual Life Res       Date:  2000-03       Impact factor: 4.147

Review 7.  Costs of irritable bowel syndrome in the UK and US.

Authors:  Stefanie Maxion-Bergemann; Frank Thielecke; Florian Abel; Rito Bergemann
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.

Authors:  G Dobrilla; B P Imbimbo; L Piazzi; G Bensi
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

Review 9.  Coeliac disease in primary care: case finding study.

Authors:  H Hin; G Bird; P Fisher; N Mahy; D Jewell
Journal:  BMJ       Date:  1999-01-16

10.  Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome.

Authors:  H W Nolen; D R Friend
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.